Table 3. Therapeutic management of breast cancer. A Coruña, Spain, 2013-2015.
| n (%) | 95% CI* | ||
| Adjuvant treatment (Yes) | 266 (78,5) | 73,9-83,0 | |
| Surgical Treatment | |||
| No Surgery | 3 (0,9) | 0,2-2,6 | |
| Unilateral surgery | 264 (77,9) | 73,3-82,4 | |
| Bilateral surgery | 72 (21,2) | 16,7-25,7 | |
| Type of surgery | |||
| Lumpectomy | 167 (49,7) | 44,2-55,2 | |
| Oncoplastic surgery | 81 (24,1) | 19,4-28,8 | |
| Modified radical mastectomy | 40 (11,9) | 8,3-15,5 | |
| Simple mastectomy | 34 (10,1) | 6,7-13,5 | |
| Skin-sparing mastectomy | 9 (2,7) | 0,8-4,5 | |
| Skin and nipple-sparing mastectomy | 3 (0,9) | 0,2-2,6 | |
| Axillary lymphadenectomy only | 1 (0,3) | 0,0-1,6 | |
| Supraclavicular mass resection | 1 (0,3) | 0,0-1,6 | |
| Areola-Nipple Complex Resection (Yes) | 92 (27,1) | 22,3-32,0 | |
| Surgical margins affected (Yes) | 48 (15,0) | 10,9-19,1 | |
| Sentinel Lymph Node Biopsy (Yes) | 292 (86,1) | 82,3-90,0 | |
| Positive Sentinel Lymph Node (Yes) | 131 (44,9) | 39,0-50,7 | |
| Extranodal extension | |||
| Yes | 77 (23,0) | 18,3-27,6 | |
| Indeterminate | 88 (26,3) | 21,4-31,1 | |
| Axillary lymphadenectomy (Yes) | 91 (26,8) | 22,2-32,0 | |
| Lymph node status in Lymphadenectomy | |||
| Micrometastasis | 7 (9,9) | 2,2-17,5 | |
| Macrometastasis | 64 (90,1) | 82,5-97,8 | |
| Breast Reconstruction (Yes) | 34 (10,0) | 6,7-13,4 | |
| Immediately | 27 (79,4) | 4,9-11,0 | |
| Deferred | 7 (20,6) | 0,4-3,7 | |
| Type of reconstruction | |||
| Tissue expander | 30 (88,2) | 72,5-96,7 | |
| Prosthesis | 4 (11,8) | 3,3-27,4 | |
| Chemotherapy (Yes) | 181 (53,4) | 47,9-58,8 | |
| Radiotherapy (Yes) | 285 (84,1) | 80,0-88,1 | |
| Hormone therapy (Yes) | 275 (81,1) | 76,8-85,4 | |
| Biological therapy anti-Her2 (Yes) | 40 (11,8) | 8,2-15,4 | |
| Rehabilitation of lymphedema (Yes) | 55 (16,2) | 12,1-20,3 | |
| Oncopsychology (Yes) | 43 (12,7) | 9,0-16,4 | |
* CI: Confidence Interval